Drug Trial Radar · NCT07662928
Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
43
Planned (sponsor's estimate)
Start
Sep 16, 2026
Primary completion
May 30, 2031
Study completion Apr 30, 2033
Sponsor
- Lead sponsor
- AIDS Malignancy ConsortiumResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI); Memorial Sloan Kettering Cancer Center
- First posted
- Jun 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial studies how well epcoritamab works in combination with the chemotherapy regimen dose adjusted etoposide, prednisone, Oncovin (vincristine), cyclophosphamide, hydroxydaunorubicin-rituximab (DA-EPOCH-R) in treating patients with high risk Burkitt lymphoma. Epcoritamab binds to a protein called CD3, which is found on T cells (a type of white blood cell). It also binds to a protein called CD20, which is found on B cells (another type of white blood cell) and some lymphoma cells. This may help the immune system kill cancer cells. Epcoritamab is a type of bispecific T-cell engager. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill cancer cells. It may also lower the body's immune response. Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's DNA and may kill cancer cells. It also blocks a certain enzyme needed for cell division and DNA repair. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Giving epcoritamab in combination with the DA-EPOCH-R regimen may be an effective treatment for patients with high risk Burkitt lymphoma.
Conditions
- Adult Burkitt Lymphoma
Interventions
Biospecimen CollectionProcedure
Undergo collection of blood and CSF
Bone Marrow AspirationProcedure
Undergo bone marrow biopsy/aspiration
Bone Marrow BiopsyProcedure
Undergo bone marrow biopsy/aspiration
Computed TomographyProcedure
Undergo PET/CT
CyclophosphamideDrug
Given IV
DoxorubicinDrug
Given IV
Echocardiography TestProcedure
Undergo ECHO
EpcoritamabBiological
Given SC
EtoposideDrug
Given IV
Magnetic Resonance ImagingProcedure
Undergo MRI
Multigated Acquisition ScanProcedure
Undergo MUGA
Positron Emission TomographyProcedure
Undergo PET/CT
PrednisoneDrug
Given PO
RituximabBiological
Given IV
VincristineDrug
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants who complete at least Cycle 3 among 10 participants (Feasibility)Time frame: Up to 3 cycles (one cycles = 21 days)
- Overall survivalTime frame: From date of study registration and the date of death from any cause, assessed up to 2 years after completion of study treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.